Navigation Links
Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
Date:5/4/2012

IRVINE, Calif., May 4, 2012 /PRNewswire/ -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal third quarter and nine months ended March 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c)

Pro-Dex, Inc. (the "Company") reported a loss from continuing operations of $513,000, or $0.16 per diluted share, for the quarter ended March 31, 2012 compared to income from continuing operations of $909,000, or $0.28 per diluted share, in the same period of fiscal 2011.  The net loss for the third quarter of fiscal 2012 was $487,000 or $0.15 per diluted share, compared to net income of $868,000 or $0.26 per diluted share in the third quarter of fiscal 2011.  Sales for the quarter ended March 31, 2012 decreased 34% to $4.5 million from $6.9 million for the corresponding quarter in 2011, and decreased 21% to $13.6 million from $17.3 million for the nine months ended March 31, 2012 and 2011, respectively.  For the nine months ended March 31, 2012, the net loss was $332,000, or $0.10 per diluted share, as compared to net income of $1.6 million, or $0.49 per diluted share for the corresponding period in 2011.  As the Company has disclosed previously, the decrease in sales and the resulting net losses were primarily the result of the continuation of a reduction in purchases of the Company's medical device products by its largest customer. The results from continuing operations for the 2012 and 2011 periods exclude the results of the Company's former Astromec product line, which was sold in February 2012 as previously announced. 

Gross profit for the quarter ended March 31, 2012 was $1.2 million, or 27%, compared to gross profit of $2.8 million, or 41%, for the year-ago period.  For the nine months ended March 31, 2012 gross profit was $4.6 million, or 34%, compared to $7.2 million and 42%, respectively,
'/>"/>

SOURCE Pro-Dex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
2. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
3. Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results
4. Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results
5. Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast
6. Pro-Dex, Inc. Named One of the Fastest Growing Public Companies in Orange County
7. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Results
8. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
9. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
10. Pro-Dex, Inc. Announces Fiscal 2011 Third Quarter Financial Results Conference Call and Webcast
11. Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 Investor-Edge has initiated ... ZGNX ), Eli Lilly and Company (NYSE: LLY ... SNY ), and Novartis AG (NYSE: ... accessed at: http://investor-edge.com/register . On Friday, December ... the Dow Jones Industrial Average lost 1.79%, to finish the ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
(Date:12/13/2014)... Ala. , Dec. 12, 2014 ... purchased the HiSeq X Ten sequencing system manufactured ... enable HudsonAlpha to produce and analyze genomic data ... stems from the Institute,s commitment to research programs ... The HiSeq X Ten provides unprecedented capacity, speed ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device ... North and South America, Europe, the Middle East, Asia ... for its 2015 Medical Device Industry Survey. Each year, ... business and market trends as well as regulatory and ... areas including:, , Overall prospects for ...
(Date:12/15/2014)... For the second year in a row, ... Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak ... at number 10. This is the first year that any ... is ranked on quality, value, and other aspects, including certifications ... of 100, and at $17.99 for 12-ounces, was also the ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... CHAPEL HILL -- When pregnant women are at high risk ... has been shown to reduce the babys chances of having ... multiple injections of corticosteroids, and a new study shows that ... of cerebral palsy among children of these mothers. , Our ...
... the great questions of neurobiology, how the brain is ... a young French scientist in an award winning project ... European Heads of Research Councils (EuroHORCS). Sonia Garel ... annually to young scientists, to pursue her ground breaking ...
... to low-glycemic carbs prevents the lethal illness, study finds ... in quick-burning carbohydrates may cause fatty liver disease, which ... a study in mice by researchers at Children,s Hospital ... it may mean that fatty liver disease can be ...
... New guidelines on the diagnosis and management of cows ... Disease in Childhood, are set to improve the standard ... food allergy in children.1 The Guidelines for the Diagnosis ... extensively hydrolysed (eHF) and amino acid-based formulas (AAF), and ...
... been awarded a National Institutes of Health (NIH) Directors ... is one of 12 recipients nationwide to win the ... award is designed to support individual scientists of exceptional ... biomedical and behavioral research. The term pioneering is used ...
... the review of approximately 12,000 emergency diagnostic imaging exams ... the midst of our research, a vigorous national debate ... prior to independent call, said Richard B. Ruchman, MD, ... and subsequently approved a new requirement that would mandate ...
Cached Medicine News:Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:EURYI project to understand how the brain wires during embryogenesis 2Health News:Diet Change Can Curb Fatty Liver Disease 2Health News:New guidelines set to improve standard of cows' milk allergy care 2Health News:New guidelines set to improve standard of cows' milk allergy care 3Health News:Decision-making by residents on-call has 'miniscule' negative impact on patient care 2
... is a hospital grade Nd: YAG laser ... precise, reliable means for performing posterior capsulotomy, ... can be used for the treatment of ... (posterior capsulotomy), and closed-angle glaucoma (iridotomy). , ...
... Laserex Ultra Q is the fundamental capsulotmy laser ... energy delivery and provides 2855% less energy in ... mJs in contemporary systems. This technology eliminates ... the risk of IOL pitting. , , ...
... a high-end, mobile ultrasound imaging system. Its ... tremendous amount of processing power for generating ... Ultrasonix imaging systems provide excellent image quality ... Pulsed Doppler, Color Doppler Color Angio, Color ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Medicine Products: